Grifols, S.A.

NASDAQ:GRFS

Drug Manufacturers - General

Healthcare
$8.47 +0.34%

+$0.03 today

Market cap
$7.17B
Beta
1.17
P/E (TTM)
14.7
EPS (TTM)
$0.61
Dividend yield
1.67%
52W Low $7.26High $11.14

Volume 0.59M

Average 0.69M

GRFS Short-term Debt

Borrowings and the current portion of long-term debt due within one year.

Grifols, S.A.NASDAQ: GRFS

Short-term Debt · Q2 FY2026 · quarter ended Jun 2026

Short-term debt rises 7.4% from a year ago

Short-term debt stood at €303M at the end of Q2 FY2026, up 7.4% from a year earlier and down 48.6% from the prior quarter. Over 3 fiscal years it compounded at -12.7% a year.

Context

  • Short-term debt amounted to 1.5% of total assets at the end of Q2 FY2026, unchanged from a year earlier.
  • Short-term debt increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether short-term debt keeps rising in the next quarterly balance sheet after a +7.4% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
€303M-48.6% QoQ
Last fiscal yearDec 2025
€385.84M-26.2% YoY
Year agoJun 2025
€282.14M+7.4% since
Short-term Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+7.4%——
1 year-26.2%——
3-year CAGR-12.7%——
5-year CAGR——
10-year CAGR——

Short-term Debt history

EUR · from the balance sheet

Latest · FY2025
385.84M EUR
Year-over-year change
-26.2%
4-year CAGR
-36.3%

Short-term Debt vs competitors

How GRFS compares with its peers on the latest reported figures

  • Peers report in different currencies, so short-term debt is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +7.4% is the 3rd highest of 7, against a peer median of -40.8%.
  • Short-term debt amounts to 1.5% of total assets for GRFS, versus a peer median of 2.3%.
GRFS Competitors
Short-term Debt for GRFS and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ABTAbbott LaboratoriesJun 2026$3.01B USD+492.7%+10.1%2.8%
BDXBecton, Dickinson and CompanySep 2026$944M USD-39.5%-9.1%1.9%
BIOBio-Rad Laboratories, Inc.Jun 2026$400.7M USD+30723.1%+333.6%3.9%
GRFSGrifols, S.A.Jun 2026€303M EUR+7.4%-12.7%1.5%
QDELQuidelOrtho CorporationMar 2026$228.2M USD-42.1%-4.9%4.1%
TECHBio-Techne CorporationSep 2026$200M USD——7.6%
HAEHaemonetics CorporationJun 2026$4.96M USD-98.4%-24.8%0.2%
ADMAADMA Biologics, Inc.Jun 2026$3.75M USD——0.5%
MRVIMaravai LifeSciences Holdings, Inc.Jun 2026$1.13M USD-79.3%+0.0%0.2%
Peer median (excluding GRFS) —-40.8%-2.5%2.3%

Competitors are the stored peer set for GRFS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents655.49M549.21M529.58M979.78M824.65M
Short-term Investments2.03B31.03M116.47M21.18M0
Net Receivables434.14M774.2M692.86M1.08B844.64M
Inventory2.26B3.24B3.48B3.56B3.29B
Other Current Assets131.63M80.88M1.31B78.58M100.96M
Total Current Assets5.51B4.69B6.13B5.73B5.07B
Property, Plant & Equipment (Net)3.34B4.28B4.19B4.31B4.05B
Goodwill6.23B7.01B6.8B7.4B6.83B
Intangible Assets1B2.95B1.21B2.93B2.73B
Long-term Investments2.27B1.99B451.9M528.97M592.75M
Tax Assets0174.92M0341.67M461.8M
Other Non-current Assets882.61M124.19M2.21B167.72M15.99M
Total Non-current Assets13.72B16.54B14.86B15.68B14.68B
Total Assets19.23B21.23B20.99B21.41B19.75B
Account Payables628.99M787.96M822.95M852.31M840.64M
Short-term Debt2.35B578.92M916.51M523.13M385.84M
Tax Payables015.69M084.99M0
Deferred Revenue037.83M070.87M76.97M
Other Current Liabilities119.44M381.59M108.6M81.95M459.8M
Total Current Liabilities3.47B2.02B2.33B2.16B2.02B
Long-term Debt6.94B8.15B8.99B8.42B7.39B
Deferred Tax Liabilities01.03B01.01B906.61M
Deferred Revenue (Non-current)015.12M013.94M0
Other Non-current Liabilities675.34M1.12B1.16B170.46M854.64M
Total Non-current Liabilities8.44B11.23B11.15B10.64B10.12B
Total Liabilities11.92B13.25B13.48B12.8B12.13B
Common Stock119.6M119.6M119.6M119.6M119.95M
Retained Earnings248M079.36M156.92M0
Accumulated OCI4.41B4.78B4.41B4.83B4.37B
Other Stockholders Equity00000
Minority Interest1.79B2.33B2.15B2.72B2.33B
Total Equity7.32B7.98B7.51B8.61B7.6B
Total Debt10.17B9.75B11.02B10.09B8.74B
Net Debt9.51B9.2B10.49B9.11B7.92B

Grifols, S.A.

NASDAQ:GRFS

Intrinsic Alpha fair value

Locked

Current Price

$8.47

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.